BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Supplementary materials



Figure S1. Experimental design and procedures.

Table S1. Inclusion criteria and exclusion criteria in this study.

Inclusion criteria:	
1	age ≥18 years
2	before 14 weeks of pregnancy
3	with the risk of VTE recurrence
	high risk: type 1 antithrombin deficiency; type 2 reactive site antithrombin defect
	moderate risk: previous precipitated VTE plus thrombophilic defect; previous unprecipitated VTE; homozygous factor V Leiden plus family medical history of VTE (FMH); homozygous prothrombin gene mutation plus FMH; heterozygous protein C deficiency plus FMH; combination of thrombophilia
4	single pregnancy confirmed by blood tests or ultrasound before gestational week 14
Exclusion criteria:	
1	Pregnant women who had diseases requiring extra LMWH for treatment such as diabetes or were allergic to LMWH
2	VTE were induced by other unrelated reasons such as surgery or major trauma